Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Buy dildos and sex toys.
Popular Articles

Drive For Good Quality Medicines, Foods Reinforced By USP Agreements With Chinese Drug Authorities
As part of its efforts to improve the quality of medicines and food ingredients worldwide, the U.S. Pharmacopeial (USP) Convention this week reached three new cooperative agreements with Chinese drug control authorities. Because Chinese manufacturers supply so much of the world"s drug and food ingredients, these agreements-coupled with three previous agreements between USP and other government organizations in China-mark a significant commitment to ensure that concerns about quality are addressed. USP is a scientific, nonprofit organization that sets standards for the quality of prescription and over-the-counter drugs that are enforced by the U.S. Food and Drug Administration (FDA) in the United States. USP also sets standards for the quality of food ingredients and dietary supplements; these and USP"s drug standards are used in more than 130 countries.
buy viagra
UK's Poorest Twice As Likely To Have Diabetes And Its Complications
The poorest people in the UK are 2.5 times more likely to have diabetes at any age than the average person, a new Diabetes UK report reveals today. And once they have the condition, those in the most deprived homes are twice as likely to develop complications of diabetes as those in the least deprived.
News of the day
Spine-shaped Gold Protrusions Improve The Adherence And Electrical Coupling Of Neurons With The Surface Of Micro-electronic Devices
Interfacing neurons with micro- and nano-electronic devices has been a subject of intense studies over the last decade and is used both in basic research and medical applications. The electronic devices used in such neuroelectronic hybrids are mainly planar metal electrodes and planar transistors.
Health Insurance

New Promising Alzheimer's Disease Treatment: Mount Sinai

Researchers at Mount Sinai School of Medicine have found that a compound called NIC5-15, might be a safe and effective treatment to stabilize cognitive performance in patients with mild to moderate Alzheimer"s disease. The two investigators, Giulio Maria Pasinetti, M.D., Ph.D. , and Hillel Grossman, M.D., presented Phase IIA preliminary clinical findings at the Alzheimer"s Association 2009 International Conference on Alzheimer"s Disease (ICAD) in Vienna on Sunday, July 12. NIC5-15"s potential to preserve cognitive performance will be further evaluated in a Phase IIB clinical trial. Early evidence suggests that NIC5-15 is a safe and tolerable natural compound that may reduce the progression of Alzheimer"s disease-related dementia by preventing the formation of beta-amyloid plaque, a waxy substance that accumulates between brain cells and impacts cognitive function. . "With Alzheimer"s disease affecting 5.2 million Americans, another 5 million with early-state disease, and nearly a half million new cases reported annually, treatments like NIC5-15 would make a significant difference in the lives of many Alzheimer"s patients," said Dr. Pasinetti, Professor of Psychiatry, Professor of Neuroscience and Professor of Geriatrics and Adult Development, in the Department of Psychiatry at Mount Sinai School of Medicine. "We are hopeful that the follow up clinical study will support this preliminary evidence." "There are no FDA-approved Alzheimer"s disease modifying drugs available today," said Dr. Hillel Grossman, Assistant Professor of Psychiatry, Co-Director of the Clinical Research Core of the Alzheimer"s Disease Research Center, and Clinical Director of the Mount Sinai Memory and Aging Center. "Current drugs approved for use help maintain cognitive function, but only for a limited time. NIC5-15 is part of a new class of natural compound we found to have the potential of precluding the generation of í²-amyloid and, eventually, attenuating cognitive deterioration in preclinical models of Alzheimer"s disease." The study was conducted at the Mount Sinai Alzheimer"s Disease Research Center (ADRC), a nationally renowned center of excellence since 1984. ADCR is a comprehensive research facility and clinical program dedicated to the study and treatment of both normal aging and Alzheimer"s disease. The Center is supported by the National Institute on Aging, a branch of the National Institutes of Health. Humanetics Corporation, manufacturers of NIC5-15, sponsored the study. Phase IIB clinical trials on NIC5-15 are expected to begin later this year. Disclosure: Dr. Pasinetti has a patent pending for the use of NIC5-15 in the treatment of Alzheimer"s disease. The patent application was filed on his behalf by the Mount Sinai School of Medicine. Dr. Pasinetti and the School of Medicine could benefit financially from the results of this trial. Mount Sinai Newsroom The Mount Sinai Hospital / Mount Sinai School of Medicine


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009